Physician profile
Jonathan Dewald
NPI 1366829293
$2,561.31
in general payments reported to CMS, 2019-2025
23 companies · $604 in 2025
The $604 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $38.17 · 2021: $161 · 2022: $410 · 2023: $668 · 2024: $555 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,827.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $505.66 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.14 | 2021-2025 | Ofev, Jascayd, Stiolto Respimat |
| Glaxosmithkline, LLC. | $387.77 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Grifols USA, LLC | $202.57 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $186.10 | 2021-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $133.39 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Insmed, INC. | $129.45 | 2022-2025 | Arikayce, Brinsupri |
| Teva Pharmaceuticals USA, INC. | $112.26 | 2021-2023 | |
| Genentech, INC. | $87.53 | 2025 | |
| Abbvie INC. | $58.48 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.05 | 2022-2024 | Glassia |
| Shionogi INC | $51.81 | 2022-2024 | Fetroja |
| United Therapeutics Corporation | $45.44 | 2025 | Tyvaso |
| Alcresta Therapeutics, INC. | $22.94 | 2025 | Relizorb |
| Genzyme Corporation | $21.62 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $20.00 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $19.91 | 2024 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $18.17 | 2020 | |
| Genentech USA, INC. | $17.57 | 2024 | Xolair |
| Pfizer INC. | $16.40 | 2024 | |
| Amgen INC. | $13.81 | 2025 | Tezspire |
| La Jolla Pharmaceutical Company | $13.52 | 2023 | Giapreza |
| Idorsia Pharmaceuticals US INC | $12.72 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Dewald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.